| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BIX-01294 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.045 | 0.3 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.03 | 0.3 |